178 related articles for article (PubMed ID: 23624523)
1. High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma.
Droeser RA; Güth U; Eppenberger-Castori S; Stadlmann S; Hirt C; Terracciano L; Singer G
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1295-302. PubMed ID: 23624523
[TBL] [Abstract][Full Text] [Related]
2. MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity.
Droeser RA; Mechera R; Däster S; Weixler B; Kraljević M; Delko T; Güth U; Stadlmann S; Terracciano L; Singer G
BMC Cancer; 2016 Aug; 16():639. PubMed ID: 27531373
[TBL] [Abstract][Full Text] [Related]
3. High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy.
Ramser M; Eichelberger S; Däster S; Weixler B; Kraljević M; Mechera R; Tampakis A; Delko T; Güth U; Stadlmann S; Terracciano L; Droeser RA; Singer G
BMC Cancer; 2018 Apr; 18(1):425. PubMed ID: 29661166
[TBL] [Abstract][Full Text] [Related]
4. Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma.
Hagemann AR; Hagemann IS; Cadungog M; Hwang WT; Patel P; Lal P; Hammond R; Gimotty PA; Chu CS; Rubin SC; Birrer MJ; Powell DJ; Feldman MD; Coukos G
Cancer Biol Ther; 2011 Aug; 12(4):367-77. PubMed ID: 21785280
[TBL] [Abstract][Full Text] [Related]
5. High density of CD66b in primary high-grade ovarian cancer independently predicts response to chemotherapy.
Posabella A; Köhn P; Lalos A; Wilhelm A; Mechera R; Soysal S; Muenst S; Güth U; Stadlmann S; Terracciano L; Droeser RA; Zeindler J; Singer G
J Cancer Res Clin Oncol; 2020 Jan; 146(1):127-136. PubMed ID: 31853662
[TBL] [Abstract][Full Text] [Related]
6. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.
Leonard B; Starrett GJ; Maurer MJ; Oberg AL; Van Bockstal M; Van Dorpe J; De Wever O; Helleman J; Sieuwerts AM; Berns EM; Martens JW; Anderson BD; Brown WL; Kalli KR; Kaufmann SH; Harris RS
Clin Cancer Res; 2016 Sep; 22(18):4746-55. PubMed ID: 27016308
[TBL] [Abstract][Full Text] [Related]
8. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy.
Bösmüller H; Haitchi-Petnehazy S; Webersinke G; Marschon R; Roithmeier F; Stummvoll W; Fehm T; Klier-Richter M; Bonzheim I; Staebler A; Fend F
Virchows Arch; 2011 Aug; 459(2):183-91. PubMed ID: 21713364
[TBL] [Abstract][Full Text] [Related]
10. Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma.
Pölcher M; Braun M; Friedrichs N; Rudlowski C; Bercht E; Fimmers R; Sauerwald A; Keyver-Paik MD; Kübler K; Büttner R; Kuhn WC; Hernando JJ
Cancer Immunol Immunother; 2010 Jun; 59(6):909-19. PubMed ID: 20087581
[TBL] [Abstract][Full Text] [Related]
11. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.
De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
13. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
[TBL] [Abstract][Full Text] [Related]
14. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
15. High density of CXCL12-positive immune cell infiltration predicts chemosensitivity and recurrence-free survival in ovarian carcinoma.
Köhn P; Lalos A; Posabella A; Wilhelm A; Tampakis A; Caner E; Güth U; Stadlmann S; Spagnoli GC; Piscuoglio S; Richarz S; Delko T; Droeser RA; Singer G
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17943-17955. PubMed ID: 37966614
[TBL] [Abstract][Full Text] [Related]
16. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer.
Jäntti T; Luhtala S; Mäenpää J; Staff S
Tumour Biol; 2020 Nov; 42(11):1010428320971404. PubMed ID: 33169632
[TBL] [Abstract][Full Text] [Related]
17. Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma.
Townsend KN; Spowart JE; Huwait H; Eshragh S; West NR; Elrick MA; Kalloger SE; Anglesio M; Watson PH; Huntsman DG; Lum JJ
PLoS One; 2013; 8(12):e82406. PubMed ID: 24376535
[TBL] [Abstract][Full Text] [Related]
18. Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer.
Scurry J; van Zyl B; Gulliver D; Otton G; Jaaback K; Lombard J; Vilain RE; Bowden NA
Gynecol Oncol; 2018 Nov; 151(2):306-310. PubMed ID: 30194007
[TBL] [Abstract][Full Text] [Related]
19. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
